Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Biochemically Recurrent Prostate Cancer × darolutamide × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 23 Salivary Gland Neoplasms 3 Metastatic Castration-resistant Prostate Cancer 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Neoplasms 1 Neoplasm Metastasis 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Carcinoma, Intraductal, Noninfiltrating 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Cancer Female 1 Biochemically Recurrent Prostate Cancer 1

Interventions

enzalutamide 1 darolutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05526248 2026-03-11

ARAMON

Bayer

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡